Abstract: Abstract: Objective To evaluate the feasibility of application of single and dual antiplatelet aggregation therapy in high sensitive C- reactive protein (hs- CRP) level in patients with angina pectoris. Methods Ninety- six hospitalized patients with angina 6~48 h (hs-CRP < 2 mg/L) were selected and randomly divided into single aspirin group (aspirin 100 mg/d, n=48) and aspirin plus clopidogrel combination therapy group (aspirin 100 mg/d and clopidogrel 75 mg/d, n=48). The efficacy was evaluated after 30-day treatment. Data of composite end points were analyzed by follow-up in patients within 6 months. Results The total effective rates were 85.42% for combination therapy group and 81.25% for single aspirin group. There was no significant difference in total effective rate between two groups (P > 0.05). There were no significant differences in events of composite end points in patients after treatment between two groups (P > 0.05). Conclusion For angina pectoris patients with hs-CRP < 2 mg/L, the risk of cardiovascular events is relatively little. There is no obvious difference in curative effect between single and dual antiplatelet aggreration therapies.

Key words:  hypersensitive C- reactive protein, angina pectoris, coronary artery disease, antiplatelet aggregation therapy, aspirin, clopidogrel hydrogen sulfate